FDA Grants Breakthrough Therapy Designation to cPMP Replacement Therapy for Patients with Molybdenum Cofactor Deficiency (MoCD) Type A

25-10-2013 Business Wire HealthComments (0)

Alexion PharmaceuticalsPharmaceutical

Alexion ALXN announced FDA Breakthrough Therapy designation for cyclic pyranopterin monophosphate (cPMP, ALXN1101) enzyme cofactor replacement therapy for molybdenum cofactor deficiency (MoCD) type A

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top